In conclusion, the present study demonstrated that the EGFR tyrosine kinase inhibitor, erlotinib, combined with ionizing radiation induced cell cycle arrest at the G2/M phase and reduced tumor volume in a xenograft model. Here, EGFR is linked to neoplasm.